Kudahetti et al., 2009 - Google Patents
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancerKudahetti et al., 2009
- Document ID
- 3141809492637797170
- Author
- Kudahetti S
- Fisher G
- Ambroisine L
- Foster C
- Reuter V
- Eastham J
- Møller H
- Kattan M
- Cooper C
- Scardino P
- Cuzick J
- Berney D
- Publication year
- Publication venue
- BJU international
External Links
Snippet
OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long‐term follow‐up available. PATIENTS AND METHODS We examined p53 …
- 206010060862 Prostate cancer 0 title abstract description 29
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kudahetti et al. | p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer | |
| Egevad et al. | Prognostic value of the Gleason score in prostate cancer | |
| Cuzick et al. | Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort | |
| Cuzick et al. | Long-term outcome among men with conservatively treated localised prostate cancer | |
| Attard et al. | Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer | |
| Moussa et al. | Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer | |
| Eggener et al. | Gleason 6 prostate cancer: translating biology into population health | |
| Pierorazio et al. | Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy | |
| Lai et al. | Tumour budding is a reproducible index for risk stratification of patients with S tage II colon cancer | |
| Green et al. | KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach | |
| Ulase et al. | Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference | |
| Kaffenberger et al. | ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma | |
| Severi et al. | A three‐protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease | |
| Mohammed et al. | Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer | |
| Sæter et al. | The prognostic value of reactive stroma on prostate needle biopsy: a population‐based study | |
| Servoll et al. | Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer | |
| Gaya et al. | ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer | |
| Jhavar et al. | Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance | |
| Wang et al. | Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers | |
| Samaratunga et al. | Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases | |
| Ahmad et al. | Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively | |
| Chida et al. | A novel risk‐scoring system for predicting lymph node metastasis of rectal neuroendocrine tumors | |
| Oxley et al. | p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy | |
| Sengupta et al. | After radical retropubic prostatectomy ‘insignificant’prostate cancer has a risk of progression similar to low‐risk ‘significant’cancer | |
| Galiabovitch et al. | Routinely reported ‘equivocal’lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes |